These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11722508)

  • 1. The cytology of HIV-induced immunosuppression. Changing pattern of disease in the era of highly active antiretroviral therapy.
    Kocjan G; Miller R
    Cytopathology; 2001 Oct; 12(5):281-96. PubMed ID: 11722508
    [No Abstract]   [Full Text] [Related]  

  • 2. Neurological manifestations of HIV-1 infection in the HAART era.
    Geraci AP; Simpson DM
    Compr Ther; 2001; 27(3):232-41. PubMed ID: 11569325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid organ transplantation in HIV-infected individuals: obstacles and opportunities.
    Fishman JA; Rubin RH
    Transplant Proc; 2001; 33(1-2):1310-4. PubMed ID: 11267303
    [No Abstract]   [Full Text] [Related]  

  • 4. Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression.
    Iser DM; Avihingsanon A; Wisedopas N; Thompson AJ; Boyd A; Matthews GV; Locarnini SA; Slavin J; Desmond PV; Lewin SR
    AIDS; 2011 Jan; 25(2):197-205. PubMed ID: 21076271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of prophylaxis for HIV-associated opportunistic infections in the era of highly active antiretroviral therapy.
    Hermsen ED; Wynn HE; McNabb J
    Am J Health Syst Pharm; 2004 Feb; 61(3):245-56. PubMed ID: 14986554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuing Pneumocystis carinii prophylaxis.
    Girard PM
    N Engl J Med; 2001 Jan; 344(3):222-3. PubMed ID: 11172146
    [No Abstract]   [Full Text] [Related]  

  • 7. Discontinuing prophylaxis against Pneumocystis carinii pneumonia.
    Le Moal G; Breux JP; Roblot F
    N Engl J Med; 2001 May; 344(21):1639-41. PubMed ID: 11374363
    [No Abstract]   [Full Text] [Related]  

  • 8. Pneumocystis carinii pneumonia after the discontinuation of secondary prophylaxis.
    Degen O; ven Lunzen J; Horstkotte MA; Sobottka I; Stellbrink HJ
    AIDS; 2002 Jul; 16(10):1433-4. PubMed ID: 12131226
    [No Abstract]   [Full Text] [Related]  

  • 9. Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy.
    van Elden LJ; Walenkamp AM; Lipovsky MM; Reiss P; Meis JF; de Marie S; Dankert J; Hoepelman AI
    AIDS; 2000 Dec; 14(17):2787-8. PubMed ID: 11125898
    [No Abstract]   [Full Text] [Related]  

  • 10. Cryptococcal disease and HIV infection.
    Waters L; Nelson M
    Expert Opin Pharmacother; 2005 Dec; 6(15):2633-44. PubMed ID: 16316302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The house is burning: an HIV clinician's view after 20 years.
    Follansbee S
    Focus; 2001 Aug; 16(9):1-5. PubMed ID: 11692445
    [No Abstract]   [Full Text] [Related]  

  • 12. The changing role of HIV-associated oral candidiasis in the era of HAART.
    Patuwo C; Young K; Lin M; Pardi V; Murata RM
    J Calif Dent Assoc; 2015 Feb; 43(2):87-92. PubMed ID: 25868223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical epidemiology of Hodgkin lymphoma in HIV-infected patients in the highly active antiretroviral therapy (HAART) era.
    Vilchez RA; Finch CJ; Jorgensen JL; Butel JS
    Medicine (Baltimore); 2003 Mar; 82(2):77-81. PubMed ID: 12640183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy.
    Tirelli U; Spina M; Gaidano G; Vaccher E; Franceschi S; Carbone A
    AIDS; 2000 Aug; 14(12):1675-88. PubMed ID: 10985303
    [No Abstract]   [Full Text] [Related]  

  • 15. Highly active antiretroviral therapy for patients with tuberculosis: the solution or the problem?
    Boix V; Merino E; Portilla J
    AIDS; 2002 Jul; 16(10):1436-7. PubMed ID: 12131228
    [No Abstract]   [Full Text] [Related]  

  • 16. Natural history of HIV infection in the era of combination antiretroviral therapy.
    Moore RD; Chaisson RE
    AIDS; 1999 Oct; 13(14):1933-42. PubMed ID: 10513653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the benefits and limits of highly active antiretroviral therapy.
    D'Aquila R; Walker B
    JAMA; 1999 Nov; 282(17):1668-9. PubMed ID: 10553795
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic value of changes in CD4 count and HIV RNA during the first six months on highly active antiretroviral therapy in chronic human immunodeficiency virus infection.
    Ormaasen V; Bruun JN; Sandvik L; Holberg-Petersen M; Gaarder PI
    Scand J Infect Dis; 2003; 35(6-7):383-8. PubMed ID: 12953949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initiating antiretroviral therapy during HIV infection: confusion and clarity.
    Pomerantz RJ
    JAMA; 2001 Nov; 286(20):2597-9. PubMed ID: 11722276
    [No Abstract]   [Full Text] [Related]  

  • 20. Images in HIV/AIDS. Fatal progressive multifocal leukoencephalopathy: still a problem in the era of highly active antiretroviral therapy.
    Cole J; Aboulafia DM
    AIDS Read; 2009 Mar; 19(3):110-2. PubMed ID: 19334327
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.